Clinical Trials Logo

Clinical Trial Summary

This is a Phase 3, multi-site, non-randomized, open-label study evaluating the safety and efficacy of MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg for the treatment of Complicated Intra-abdominal Infections (cIAI) in Japanese participants. Efficacy will be primarily assessed by clinical response defined as complete resolution or significant improvement in signs and symptoms of the index infection.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02739997
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date April 8, 2016
Completion date July 28, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05905055 - P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales Phase 3
Completed NCT03293485 - Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) Phase 3
Recruiting NCT05148702 - EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection. Phase 3
Completed NCT04927312 - Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection Phase 3
Completed NCT00929643 - Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections N/A
Completed NCT01499290 - Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections Phase 3
Completed NCT01147640 - Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections Phase 2
Completed NCT01726023 - Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections Phase 3
Completed NCT01644643 - Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens Phase 3
Withdrawn NCT00914888 - Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia Phase 3
Withdrawn NCT01602874 - Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia Phase 3
Completed NCT01265784 - Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections Phase 2
Completed NCT00157898 - A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED) Phase 4
Recruiting NCT05733104 - A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
Completed NCT01445678 - Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections Phase 3
Completed NCT03329092 - A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. Phase 3
Completed NCT03217136 - MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) Phase 2
Completed NCT01500239 - A Study Comparing Ceftazidime-Avibactam+Metronidazole Versus Meropenem in Adults With Complicated Intra-abdominal Infections Phase 3